The Tissue Diagnostic Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Tissue Diagnostic Market:
https://www.thebusinessresearchcompany.com/report/tissue-diagnostic-global-market-report
According to The Business Research Company’s Tissue Diagnostic Global Market Report 2024, The tissue diagnostic market size has grown rapidly in recent years. It will grow from $5.27 billion in 2023 to $5.92 billion in 2024 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to aging population, cancer prevalence, technological advancements, increased disease awareness, pathology workflow efficiency..
The tissue diagnostic market size is expected to see rapid growth in the next few years. It will grow to $9.48 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to personalized medicine growth, rise of liquid biopsies, ai and machine learning adoption, telepathology expansion, minimally invasive techniques. Major trends in the forecast period include digital pathology, artificial intelligence (ai),telepathology services, multiplex staining and imaging, integration of genomic data..
The rising incidence of cancer will propel the growth of the tissue diagnostic market during the forecast period. Cancer begins when genetic changes interfere, and cells start to grow uncontrollably and destroy body tissue and form a mass called a tumor. A tumor can be cancerous or benign. Cancer can be caused due to various reasons such as genetic mutations, cancer-causing chemicals (carcinogens), smoking, obesity, radiation, hormones, and others. As the instances of occurring cancer increase, there will be a significant need for diagnostic procedures such as tissue diagnostics help in determining the disease state. For instance, according to the US voluntary health organization dedicated to eliminating cancer, the American Cancer Society, in the USA, there were expected to be 1.8 million new cancer cases identified and 606,520 cancer deaths in 2020, and the number was expected to increase to 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in 2021. Therefore, the rising incidence of cancer drives the growth of the tissue diagnostic market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=6505&type=smp
The tissue diagnostic market covered in this report is segmented –
1) By Product: Consumables, Antibodies, Kits, Reagents, Probes, Instruments, Slide Staining System, Scanner, Tissue Processing system
2) By Technology: Immunohistochemistry (IHC), In Situ Hybridization (ISH), Digital Pathology And Workflow Management, Special Staining
3) By Disease: Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-Small Cell Lung Cancer (NSCLC)
4) By End User: Hospitals, Research Laboratories, Pharmaceutical Companies, Contract Research Organizations
Product innovation is a key trend gaining popularity in the tissue diagnostic market. Product innovations include the introduction of innovative products and solutions that collect multiple sample types, test multiple samples simultaneously, automate lab operations, and make them accessible to everyone. Key players are focused on developing and offering these automated tissue diagnostic systems to gain a competitive edge in the market and increase revenue. For instance, in May 2021, QIAGEN N.V., a Netherlands-based provider of sample and assay technologies for molecular diagnostics, introduced the first FDA-approved tissue companion diagnostic, the Therascreen KRAS Kit detects the KRAS G12C mutation in NSCLC tumors, expanding precision therapy options in lung cancer. It is the first companion diagnostic test to receive premarket approval from the United States Food and Drug Administration (FDA) for use in identifying the KRAS G12C mutation in NSCLC tumor tissue samples.
The tissue diagnostic market report table of contents includes:
.
.
.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Overview and Scope Diagnostic specialty antibodies refer to a class of antibodies that are specifically…
Overview and Scope Diabetic retinopathy is an eye condition that can lead to blindness and…
Overview and Scope Ocular inflammation treatment refers to medical approaches aimed at reducing swelling and…
Overview and Scope Polymerase chain reaction (PCR) is a laboratory technique used to amplify specific…
Overview and Scope Quantum security refers to the process of using quantum mechanical principles to…
Overview and Scope A smart bandage is an advanced medical dressing or wound care device…